Personal information

No personal information available

Activities

Collapse all

Employment (3)

Boehringer Ingelheim (Austria): Vienna, Vienna, AT

2021-08-01 to present | Associate Scientific Director (Drug Discovery Sciences - Discovery ADME)
Employment
Source: Self-asserted source
Lydia Woelflingseder

University of Natural Resources and Life Science (BOKU) Vienna: Vienna, AT

2020-01 to present | Postdoctoral Researcher (Institute of Plant Protection)
Employment
Source: Self-asserted source
Lydia Woelflingseder

University of Vienna: Vienna, AT

2016-06 to 2019-06 | Scientific Research Assistant (praedoc) (Department of Food Chemistry and Toxicology)
Employment
Source: Self-asserted source
Lydia Woelflingseder

Education and qualifications (1)

University of Vienna: Vienna, AT

2016-06 to 2019-06 | Scientific Research Assistant (praedoc) (Department of Food Chemistry and Toxicology)
Qualification
Source: Self-asserted source
Lydia Woelflingseder

Works (15)

Data from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.c.7623351
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193748
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193745
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193742
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193739
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193736
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193733
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 4 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193730
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 5 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193727
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 6 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193724
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 7 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193721
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Cancer Discovery
2025-01-13 | Journal article
DOI: 10.1158/2159-8290.CD-24-0306
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Exploring the dermotoxicity of the mycotoxin deoxynivalenol: combined morphologic and proteomic profiling of human epidermal cells reveals alteration of lipid biosynthesis machinery and membrane structural integrity relevant for skin barrier function

Archives of Toxicology
2021-06 | Journal article
DOI: 10.1007/s00204-021-03042-y
Contributors: Giorgia Del Favero; Lukas Janker; Benjamin Neuditschko; Julia Hohenbichler; Endre Kiss; Lydia Woelflingseder; Christopher Gerner; Doris Marko
Source: check_circle
Crossref

Pro-Inflammatory Effects of NX-3 Toxin Are Comparable to Deoxynivalenol and not Modulated by the Co-Occurring Pro-Oxidant Aurofusarin

Microorganisms
2020-04-21 | Journal article
DOI: 10.3390/microorganisms8040603
Contributors: Lydia Woelflingseder; Nadia Gruber; Gerhard Adam; Doris Marko
Source: check_circle
Crossref

Immunosuppressive effect of theFusariumsecondary metabolite butenolide in human colon epithelial cells

2020-04-18 | Preprint
DOI: 10.1101/2020.04.16.044388
Contributors: Lydia Woelflingseder; Gerhard Adam; Doris Marko
Source: check_circle
Crossref
How many people are using ORCID?